A Comprehensive Monograph on Coenzyme M (Mesna): From Biochemical Cofactor to Clinical Uroprotectant

Executive Summary

Coenzyme M, known pharmacologically by its generic name Mesna, is a small molecule synthetic thiol compound identified chemically as 2-mercaptoethanesulfonic acid.[1] Its application in modern medicine represents a significant achievement in targeted supportive care, particularly in oncology. The primary and critical clinical function of Mesna is the prophylaxis of hemorrhagic cystitis, a severe and dose-limiting toxicity induced by the oxazaphosphorine class of chemotherapeutic agents, which includes ifosfamide and high-dose cyclophosphamide.[1]

The pharmacological utility of Mesna is predicated on a unique and elegant mechanism of "regional detoxification." Following administration, the active Mesna is rapidly oxidized in the systemic circulation to its inactive disulfide metabolite, dimesna. This inactive form is then filtered by the kidneys and subsequently reduced back to active Mesna within the renal tubules. This process delivers a high concentration of the active, free-thiol compound directly to the bladder, where it is needed most. Here, it chemically neutralizes acrolein, the primary urotoxic metabolite of oxazaphosphorine chemotherapy, forming a stable, non-toxic conjugate that is safely excreted.[3] This pharmacokinetic-driven localization minimizes systemic interactions while maximizing protection at the target site.

While Mesna's name derives from its natural identity as a coenzyme involved in methyl-group transfer in methanogenic archaea, this biochemical role is entirely distinct from its pharmacological application, which is based purely on its chemical properties as a sulfhydryl donor.[2] Clinically, Mesna is indispensable; its use has enabled the administration of higher, more effective doses of ifosfamide and cyclophosphamide, thereby improving treatment outcomes for a range of malignancies. The agent is available in both intravenous and oral formulations, with precise dosing schedules designed to synchronize its availability in the bladder with the excretion of toxic metabolites. Despite a generally favorable safety profile, Mesna is associated with important risks, most notably severe systemic hypersensitivity and dermatologic reactions, which require vigilant clinical monitoring.[7] This monograph provides an exhaustive analysis of Mesna, from its fundamental chemical properties to its complex clinical applications, safety profile, and place in therapy.

Compound Identification and Physicochemical Properties

A foundational understanding of Mesna begins with its precise chemical identity, nomenclature, and physical characteristics. This section consolidates these details from various technical, commercial, and regulatory sources.

Nomenclature and Synonyms

The compound is known by several names depending on the context. Its formal chemical name is 2-mercaptoethanesulfonic acid.[9] In the context of its natural biological role, it is referred to as Coenzyme M.[2] For its pharmaceutical application, the International Nonproprietary Name (INN) is Mesna, which is commonly used in clinical and regulatory literature.[1] The name "Mesna" itself is an acronym derived from its chemical structure: 2-

mercaptoethane sulfonate Na (representing the sodium salt form).[12]

Numerous synonyms are used in scientific and commercial databases, including:

• 2-sulfanylethanesulfonic acid [10]
• Reduced Coenzyme M (Reduced CoM) [10]
• HS-CoM [10]
• Mercaptoethanesulfonic acid [10]

The distinction between the names "Coenzyme M" and "Mesna" is particularly important. While they refer to the same molecule, the names signify two entirely separate contexts and functions. Coenzyme M is a naturally occurring cofactor essential for the metabolism of primitive microorganisms like methanogenic archaea, where it participates in enzymatic methyl group transfer reactions.[2] Its biosynthesis in these organisms is a well-defined biological pathway. In stark contrast, Mesna is a synthetically manufactured pharmaceutical agent.[2] Its clinical utility does not derive from any coenzymatic function in humans but is entirely dependent on the non-enzymatic chemical reactivity of its thiol group as a scavenger of toxic electrophilic molecules. This distinction is critical for clinicians to avoid incorrect assumptions about its mechanism of action or the existence of an endogenous human analogue.

Molecular and Structural Details

Mesna is an organosulfonic acid characterized by a simple but functionally critical structure: an ethyl backbone connecting a thiol (sulfhydryl, -SH) group at one end and a sulfonic acid (-SO3H) group at the other.[2] This bifunctional nature is key to its properties; the thiol group is the main site of its chemical reactivity and protective action, while the highly polar sulfonic acid group confers excellent solubility in aqueous media, which is essential for its administration and renal excretion.[9] The molecular formula of the acid form is

C2​H6​O3​S2​.[2]

Identifiers and Physicochemical Properties

Standardized identifiers are used to uniquely define Mesna across various databases. These, along with its key physicochemical properties, are summarized in Table 2.1.

Table 2.1: Summary of Coenzyme M (Mesna) Identifiers and Physicochemical Properties

Attribute	Value	Source(s)
DrugBank ID	DB09110	1
CAS Number (Acid Form)	3375-50-6	9
CAS Number (Sodium Salt)	19767-45-4	14
FDA UNII	VHD28S0H7F	10
IUPAC Name	2-sulfanylethanesulfonic acid	2
Common Synonyms	Mesna, Coenzyme M, HS-CoM, 2-Mercaptoethanesulfonate	1
Molecular Formula	C2​H6​O3​S2​	2
Molecular Weight (Acid)	142.20 g/mol	2
Molecular Weight (Na Salt)	164.18 g/mol	14
Appearance	Colorless to light yellow powder	10
Density	1.25 g/mL (at 20 °C)	10
pKa	pK1; pK2: 9.5 (at 20°C)	10
Solubility	Soluble in water and DMSO	9

The manufacturing process for the acid form, as described in the literature, involves the ammonolysis of β-S-thiuronium ethanesulfonate, followed by purification using ion exchange resin to yield β-mercaptoethanesulfonic acid.[10]

Biological and Pharmacological Profile

The biological and pharmacological characteristics of Mesna are distinct. Its natural biochemical role is confined to microbial metabolism, while its pharmacological profile in humans is defined by its unique mechanism of action and the pharmacokinetic properties that enable it.

The Biochemical Role of Coenzyme M

In the realm of biochemistry, Coenzyme M (HS-CoM) is recognized as the smallest known organic cofactor.[6] Its function is central to the energy metabolism of methanogenic archaea, a group of ancient microorganisms. In these organisms, Coenzyme M serves as a crucial carrier of methyl groups in the terminal step of methanogenesis, the biological production of methane.[2] It is also implicated in the metabolism of alkenes in certain bacteria, where it is involved in aliphatic epoxide carboxylation.[6] The biosynthesis of Coenzyme M within these microorganisms is a complex, multi-enzyme process involving proteins such as cysteate synthase, sulfopyruvate decarboxylase, and L-sulfolactate dehydrogenase.[6] It is critical to reiterate that this biological pathway and function are not present in humans; the use of the name "Coenzyme M" for the pharmaceutical agent is a historical artifact of its initial discovery context.

Pharmacological Mechanism of Action: Regional Detoxification

As a pharmaceutical agent, Mesna functions as a cytoprotective or chemoprotective agent, specifically a uroprotectant.[1] Its mechanism is not biological in the sense of interacting with enzymes or receptors to elicit a response, but rather a direct chemical neutralization of toxic metabolites produced by chemotherapy.

The oxazaphosphorine alkylating agents, ifosfamide and cyclophosphamide, are prodrugs that are metabolized by the liver into active anticancer compounds. This metabolic process also yields highly reactive and toxic byproducts, most notably acrolein.[1] Acrolein is not effectively detoxified systemically and is excreted via the kidneys, leading to its accumulation and concentration in the bladder. In the bladder, acrolein exerts a potent urotoxic effect by causing direct damage to the urothelial cells. This damage stimulates a cascade of inflammation, characterized by the release of mediators like interleukin-1β (IL-1β) and tumor necrosis factor-alpha (TNF-α), upregulation of inducible nitric oxide synthase (iNOS), and subsequent mucosal edema, capillary fragility, and ulceration, which clinically manifests as hemorrhagic cystitis.[1]

Mesna's primary protective mechanism is to intercept and neutralize acrolein before it can damage the bladder lining. The free thiol (-SH) group of Mesna is a strong nucleophile that readily attacks the electrophilic β-carbon of acrolein, an α,β-unsaturated aldehyde. This reaction, a classic Michael addition, forms a stable and inert thioether conjugate.[5] This new compound is non-toxic and is safely excreted in the urine, effectively detoxifying the urinary tract.[5] In addition to acrolein, Mesna has also been shown to bind and detoxify 4-hydroxy-ifosfamide, another urotoxic metabolite of ifosfamide, further contributing to its protective effect.[1]

Beyond this direct chemical scavenging, evidence suggests a potential secondary mechanism that contributes to Mesna's uroprotective efficacy. Acrolein-induced inflammation involves the enzyme lactoperoxidase (LPO). It has been proposed that Mesna's sulfhydryl group can bind to the LPO enzyme at its thiocyanate binding site, inhibiting its function.[3] This action would result in a direct reduction and regulation of the local inflammatory effects within the bladder mucosa. This potential dual action—acting as both a chemical antagonist to the toxin and an inhibitor of the subsequent inflammatory response—may explain its high degree of clinical efficacy.

Pharmacokinetics: The Key to Regional Action

The clinical success and favorable safety profile of Mesna are entirely dependent on its unique pharmacokinetic properties, which effectively create a targeted drug delivery system without the need for advanced formulation technology. The process can be understood as a form of "reverse prodrug" strategy: the drug is administered in its active form, is systemically and reversibly inactivated for safe transport, and is then locally reactivated at its specific site of action.

Absorption: Following oral administration, Mesna is well absorbed. The average oral bioavailability is approximately 58% for the active free Mesna and 89% for total Mesna (which includes the inactive dimesna metabolite).[1] Peak plasma concentrations (

Cmax​) of free Mesna are achieved within 1.5 to 4 hours, while total Mesna peaks later, between 3 and 7 hours.[1] The presence of food does not significantly impact the urinary availability of Mesna, allowing for flexibility in administration relative to meals.[1]

Distribution: After intravenous administration, Mesna has an apparent volume of distribution (Vd​) of approximately 0.65 L/kg, suggesting it distributes throughout the body's total water volume.[1] It exhibits low plasma protein binding (around 28% for total mesna), meaning most of the drug is free in the circulation and available for metabolism and excretion.[1] Critically, Mesna does not readily cross the blood-brain barrier, limiting its potential for central nervous system effects.[16]

Metabolism and Regional Activation: The metabolic pathway of Mesna is the cornerstone of its regional detoxification mechanism. In the bloodstream, Mesna is subject to rapid auto-oxidation. Its reactive thiol group is quickly oxidized to form its major metabolite, mesna disulfide, also known as dimesna.[1] Dimesna is a pharmacologically inert and stable molecule. This rapid systemic inactivation is crucial, as it prevents the reactive Mesna from interacting with systemic proteins and enzymes, thereby avoiding potential systemic toxicity.

Excretion and Reactivation: Dimesna, along with any remaining free Mesna, is efficiently filtered by the glomeruli of the kidneys and enters the renal tubules for excretion.[1] During its passage through the renal tubules, a significant portion of the inactive dimesna is acted upon by enzymes on the luminal membrane of the tubular cells, such as glutathione dihydrogenase.[1] These enzymes reduce the disulfide bond of dimesna, regenerating the active, free-thiol form of Mesna.[1] This reactivated Mesna is then excreted directly into the bladder urine, precisely where the urotoxic metabolites of chemotherapy are accumulating. This elegant process ensures that a high concentration of the protective agent is delivered specifically to the target organ, while systemic exposure to the reactive form is minimized.

The elimination half-life (t1/2​) reflects this rapid process. The half-life of active Mesna is very short, reported as 0.36 hours (approximately 22 minutes), while the half-life of the inactive dimesna is longer at 1.17 hours.[1] Other studies have reported an even faster initial half-life for IV Mesna of just 9 to 11 minutes, consistent with its rapid oxidation.[17] This pharmacokinetic profile necessitates the fractionated dosing schedules used in clinical practice to ensure a sustained protective concentration in the bladder throughout the period of acrolein excretion.

Table 3.1: Key Pharmacokinetic Parameters of Mesna and its Metabolite Dimesna

Parameter	Mesna (Active Form)	Dimesna (Inactive Metabolite)	Source(s)
Oral Bioavailability	~58% (free) / 89% (total)	N/A	1
Time to Peak (Oral)	1.5 - 4 hours	3 - 7 hours	1
Elimination Half-life (t1/2​)	0.36 hours	1.17 hours	1
Volume of Distribution (Vd​)	0.652 L/kg (IV)	N/A	1
Plasma Clearance	1.23 L/h/kg	N/A	1
Renal Excretion (% of IV dose in 24h)	~32%	~33%	1

Clinical Applications and Efficacy

Mesna's clinical utility is firmly established in oncology supportive care, with a specific approved indication and widespread off-label use. Furthermore, its unique chemical properties have prompted investigation into novel therapeutic applications beyond uroprotection.

Approved and Established Off-Label Indications

The primary clinical role of Mesna is to mitigate the urotoxicity of oxazaphosphorine chemotherapy.

FDA-Approved Indication: Mesna is officially approved by the U.S. Food and Drug Administration (FDA) as a prophylactic agent to reduce the incidence of ifosfamide-induced hemorrhagic cystitis.[3] The prescribing information explicitly states a limitation of use: Mesna is not indicated to reduce the risk of hematuria resulting from other pathological conditions, such as chemotherapy-induced thrombocytopenia.[3]

Established Off-Label Use: While its formal approval is tied to ifosfamide, Mesna's use with high-dose cyclophosphamide is a universally accepted standard of care and is recommended in numerous clinical guidelines.[3] The underlying mechanism of toxicity (acrolein production) and protection is identical for both drugs, making its application with cyclophosphamide a logical and necessary extension of its approved use.[1] It is an essential component of high-dose cyclophosphamide regimens used in bone marrow transplantation and for various rheumatologic and malignant conditions.[19]

Review of Clinical Trials and Investigational Uses

The clinical trial landscape for Mesna reveals two distinct roles: its ubiquitous function as an "enabling" agent that is essential for the safety of other drugs, and its emerging potential as a primary "therapeutic" agent for new indications.

Mesna as an Enabling Agent in Oncology Trials: In the vast majority of clinical trials involving Mesna, it is not the drug under investigation. Instead, it serves as a mandatory component of supportive care, enabling the safe administration of ifosfamide or cyclophosphamide. Its presence is a prerequisite for evaluating the efficacy of the primary antineoplastic regimen. Examples of this role are seen across a wide spectrum of cancers:

• Hematologic Malignancies: Mesna is included in treatment protocols for refractory B-cell Acute Lymphoblastic Leukemia (ALL) (e.g., NCT05032183) and in preparative regimens for autologous stem cell transplantation in Multiple Myeloma (e.g., NCT00177047).[21] It is also a key component of the hyper-CVAD regimen used in adult ALL.[23]
• Solid Tumors: Investigational protocols for pediatric Central Nervous System Embryonal Tumors (e.g., NCT06942039) and soft tissue sarcomas include Mesna to support high-dose ifosfamide.[23] A recent trial in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) demonstrated that an ifosfamide/mesna combination had appreciable efficacy and a manageable safety profile, suggesting a potential new role for this combination in a difficult-to-treat population (NCT06236789).[25]
• Germ Cell Tumors: Mesna is a standard component of salvage chemotherapy regimens for testicular cancer that include ifosfamide.[26]

Mesna as an Investigational Therapeutic Agent: A smaller but growing body of research is exploring new therapeutic uses for Mesna that leverage its chemical properties beyond simple acrolein scavenging.

• Doxorubicin-Induced Toxicity: Based on preclinical data showing that Mesna could prevent certain types of doxorubicin-induced protein damage in mice, a clinical trial (NCT01205503) was completed to assess whether Mesna could block doxorubicin-induced plasma protein oxidation in cancer patients. The hypothesis was that this could be a first step in preventing the subsequent cognitive and cardiac dysfunction associated with anthracycline therapy.[28] This trial explores Mesna's potential as a broader antioxidant.
• Post-ERCP Pancreatitis: A randomized clinical trial has investigated the efficacy of Mesna in preventing pancreatitis following endoscopic retrograde cholangiopancreatography (ERCP), a common and serious complication of the procedure.[29] This application likely seeks to capitalize on its potential anti-inflammatory properties.
• Mucolytic Agent: Outside of North America, Mesna is marketed under brand names such as Mistabron® and Mistabronco® for use as a mucolytic agent.[10] Its mechanism is similar to that of acetylcysteine, using its free thiol group to break disulfide bonds in mucoproteins, thereby reducing the viscosity of mucus.
• Cholesteatoma Treatment: There is emerging off-label use of topical Mesna for the chemically-assisted dissection of recurrent and residual cholesteatoma, particularly in pediatric patients.[3] This application also capitalizes on its mucolytic capabilities.

Dosage, Administration, and Formulations

The correct administration of Mesna is paramount to its efficacy. The dosage and timing are meticulously designed to ensure that protective concentrations of the active drug are present in the bladder concurrently with the excretion of urotoxic chemotherapy metabolites.

Commercial Formulations and Brand Names

Mesna is commercially available in two primary formulations:

1. Injection Solution: Typically supplied as a 100 mg/mL solution in multidose vials (e.g., 1 g in 10 mL) for intravenous administration.[1]
2. Oral Tablets: Available as 400 mg film-coated, functionally scored tablets.[7]

The most widely recognized brand name in the United States is Mesnex®, marketed by Baxter Healthcare.[31] In Canada and Europe, it is also sold as

Uromitexan®.[12] The market includes numerous generic versions from manufacturers such as Fresenius Kabi, Hikma, and Sagent Pharmaceuticals.[31] Combination products containing both ifosfamide and Mesna are available under the brand name

Ifex/Mesnex.[27]

Recommended Dosing Regimens

Mesna dosage is always calculated based on the dose of the accompanying oxazaphosphorine agent (ifosfamide or cyclophosphamide) and is expressed as a percentage of the chemotherapy dose by weight (w/w). The chosen dosing schedule must be repeated on each day that chemotherapy is administered.[7] The specific timing of the doses is not arbitrary but is a critical clinical application of pharmacokinetic principles. Given Mesna's very short half-life of approximately 22 minutes [1], a single dose would be cleared from the body long before all the urotoxic acrolein is generated and excreted. The fractionated dosing schedules are therefore essential to maintain a continuous protective concentration of active Mesna in the urine throughout the entire period of risk.

Two standard dosing schedules are approved and widely used, as detailed in Table 5.1.

Table 5.1: Comparison of Standard Mesna Dosing Regimens

Time Point	All-Intravenous Regimen (Dose as % of Ifosfamide)	IV/Oral Regimen (Dose as % of Ifosfamide)	Route
0 Hours	20%	20%	Intravenous (IV)
2 Hours	-	40%	Oral (PO)
4 Hours	20%	-	Intravenous (IV)
6 Hours	-	40%	Oral (PO)
8 Hours	20%	-	Intravenous (IV)
Total Daily Dose	60%	100%	Mixed
Source: 7

Key Administration Considerations:

• The higher total daily dose in the IV/Oral regimen (100% vs. 60%) is necessary to compensate for the incomplete oral bioavailability of Mesna (approximately 50-60%), ensuring comparable protective levels in the urine.[1]
• The IV/Oral regimen is often preferred for outpatient settings to reduce the need for patients to remain in a clinical facility for the 4- and 8-hour IV doses.[17]
• If a patient vomits within two hours of taking an oral Mesna tablet, the dose must be repeated, or an intravenous dose should be administered to ensure adequate protection.[4]

Preparation, Handling, Stability, and Incompatibilities

Proper handling of Mesna is essential for safety and efficacy.

• Preparation for IV Administration: Mesna injection must be diluted prior to administration to a final concentration of 20 mg/mL. Compatible diluents include 5% Dextrose Injection (D5W), 0.9% Sodium Chloride Injection (Normal Saline), and various combinations of dextrose and saline, as well as Lactated Ringer's Injection.[7]
• Stability: Once diluted, Mesna solutions are chemically and physically stable for 24 hours at room temperature (25°C / 77°F). The multidose vials may be stored and used for up to 8 days after the initial puncture.[7]
• Drug Incompatibilities: Mesna is chemically incompatible in vitro and should not be mixed in the same infusion solution with the platinum-based drugs cisplatin and carboplatin, or with nitrogen mustard.[37] Mixing Mesna with the anthracycline epirubicin results in the inactivation of epirubicin and must be avoided.[37]
• Interaction with Ifosfamide: While Mesna is administered with ifosfamide, the benzyl alcohol preservative contained in Mesna injection vials can reduce the stability of ifosfamide. They may be mixed in the same infusion bag only if the final concentration of ifosfamide does not exceed 50 mg/mL. Higher concentrations may be incompatible.[3]

Safety, Toxicology, and Risk Management

The safety profile of Mesna is generally considered favorable, but it is associated with specific risks that require careful management. A nuanced understanding of its adverse effects requires differentiating events caused by Mesna itself from those confounded by the highly toxic chemotherapy agents with which it is co-administered.

Adverse Effect Profile

A sophisticated analysis of Mesna's safety profile can be achieved by comparing adverse event data from trials where it was given with chemotherapy to data from studies in healthy volunteers who received Mesna alone.

Adverse Effects Likely Confounded by Concomitant Chemotherapy:

In clinical trials where Mesna is given with ifosfamide or cyclophosphamide, a high incidence of adverse events is reported. However, the majority of these are classic and expected toxicities of the alkylating agents themselves. These include 1:

• Hematologic: Leukopenia, thrombocytopenia, anemia, granulocytopenia.
• Gastrointestinal: Nausea, vomiting, constipation, diarrhea, anorexia.
• Constitutional: Fatigue, asthenia (weakness), fever.
• Neurologic: Headache, somnolence (drowsiness).
• Dermatologic: Alopecia (hair loss).

While these are listed in Mesna's prescribing information, it is clinically understood that Mesna does not cause myelosuppression or alopecia; these effects are attributable to the chemotherapy.

Adverse Effects More Directly Attributable to Mesna:

Studies in healthy volunteers and consistent post-marketing reports have helped to isolate the adverse effects of Mesna itself. These include 3:

• Gastrointestinal: The most common adverse reaction, particularly with the oral formulation, is dysgeusia (a bad, unpleasant, or metallic taste), which is reported in a very high percentage of patients and can contribute to nausea.[3] Abdominal pain and diarrhea are also more frequent with oral Mesna.[35]
• Dermatologic and Hypersensitivity Reactions: These represent the most serious Mesna-specific toxicities. Reactions can range from mild flushing and rash to severe, life-threatening conditions (see below).[35]
• Constitutional: Headache and flu-like symptoms (fever, chills, myalgia) have been reported in patients receiving Mesna without concurrent chemotherapy.[35]
• Cardiovascular: Flushing is common. Hypotension, sometimes fluid-refractory, has been reported but is rare.[35]
• Injection Site Reactions: Pain or irritation at the injection site can occur, especially if the drug is not properly diluted.[35]

Contraindications, Warnings, and Precautions

Contraindications:

Mesna is strictly contraindicated in patients with a known history of a hypersensitivity reaction to Mesna or any other thiol-containing compound (e.g., amifostine).7 It is also contraindicated in those with a known hypersensitivity to any excipients in the formulation, such as the benzyl alcohol preservative found in multidose vials.7

Warnings and Precautions:

• Hypersensitivity Reactions: Mesna can provoke severe systemic hypersensitivity reactions, including anaphylaxis. These reactions can manifest with cardiovascular symptoms (hypotension, tachycardia), respiratory distress, fever, and angioedema.[1] Reactions may occur on the first exposure or be delayed, appearing only after several months of treatment.[7] An important clinical observation is that patients with a history of autoimmune disorders (e.g., systemic lupus erythematosus, rheumatoid arthritis, nephritis) appear to have a significantly increased risk of developing these hypersensitivity reactions.[4]
• Severe Dermatologic Toxicity: Life-threatening skin reactions have been reported in association with Mesna use. These include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).[8] DRESS is a multiorgan hypersensitivity that can affect the liver, kidneys, and heart.[38] Patients should be counseled to report any rash immediately, and Mesna should be discontinued if a severe cutaneous reaction is suspected.
• Benzyl Alcohol Toxicity in Neonates: The injectable formulation of Mesna contains benzyl alcohol as a preservative. This substance has been associated with a fatal "gasping syndrome" in premature and low-birth-weight infants. Therefore, the multidose vial formulation of Mesna should be avoided in this vulnerable population.[8]
• Reproductive Concerns: Mesna is almost always used with ifosfamide or cyclophosphamide, which are known teratogens. Effective contraception is mandatory for patients of reproductive potential during treatment and for a specified period after the last dose (e.g., 6 months for females, 3 months for males).[38] Breastfeeding should be avoided during treatment and for at least one week after the final dose.[38]

Drug and Laboratory Test Interactions

Mesna does not have extensive drug-drug interactions, but its chemical nature can lead to significant interference with common laboratory tests.

• Drug-Drug Interactions: As noted previously, Mesna is physically and chemically incompatible with several other drugs in solution, including cisplatin, carboplatin, nitrogen mustard, and epirubicin.[37]
• Laboratory Test Interference: The free thiol group in Mesna can react with reagents used in various diagnostic tests, leading to erroneous results. Clinicians must be aware of these potential interferences to avoid misinterpreting a patient's clinical status.
• False-Positive Urinary Ketones: Mesna reacts with nitroprusside sodium, a reagent used in many urine dipstick tests for ketones. This can produce a false-positive result, which may be mistaken for diabetic ketoacidosis or starvation ketosis.[7]
• False-Negative Enzymatic CPK Tests: Certain assays for creatinine phosphokinase (CPK) activity use a thiol compound to reactivate the enzyme. The presence of Mesna in the sample can interfere with this process, leading to a falsely low or negative CPK level, potentially masking true muscle damage.[7]
• False-Positive Ascorbic Acid Tests: Mesna can cause a false-positive reaction in urine screening tests for ascorbic acid that are based on Tillman's reagent.[7]

Comparative Analysis of Uroprotective Strategies

Mesna's establishment as the standard of care for preventing oxazaphosphorine-induced hemorrhagic cystitis is the result of demonstrated superiority over alternative strategies. It occupies a specific therapeutic niche where its combination of targeted efficacy, favorable safety, and practical application has proven superior to competitors.

Mesna versus N-Acetylcysteine (NAC)

N-acetylcysteine (NAC) was one of the first systemic agents employed for uroprotection. Like Mesna, it is a thiol-containing compound capable of neutralizing acrolein. However, clinical evidence has decisively shown Mesna to be the superior agent. A landmark comparative study in patients with refractory germ cell tumors treated with ifosfamide-based chemotherapy provided definitive results. In this trial, the incidence of hematuria was significantly lower in patients receiving Mesna (4.2%) compared to those receiving oral NAC (27.9%), a highly statistically significant difference (p<0.0001).[42]

Furthermore, Mesna demonstrated better tolerability. Oral NAC was associated with poor taste and gastrointestinal side effects like nausea and vomiting, which compromised patient compliance.[43] Most critically, Mesna was more effective at preserving the planned chemotherapy dose intensity. Dose reductions of ifosfamide due to urotoxicity were required in 11 patients in the NAC group, whereas no patients in the Mesna group required such a reduction.[42] This ability to allow the full, intended dose of chemotherapy to be delivered safely is a key component of Mesna's clinical value.

Mesna versus Amifostine

Amifostine is a broad-spectrum cytoprotective agent with a fundamentally different mechanism and clinical application compared to Mesna. Amifostine is a prodrug that is dephosphorylated in tissues to its active thiol metabolite, WR-1065. This conversion occurs preferentially in normal tissues due to higher alkaline phosphatase activity, providing selective protection of multiple organ systems (e.g., kidneys, bone marrow, oral mucosa) from the toxicities of a wide range of chemotherapy agents (like cisplatin) and radiation.[44]

While preclinical studies in rats have shown that amifostine can be as effective as Mesna in preventing cyclophosphamide-induced bladder damage [45], their clinical roles have remained distinct. Mesna's regional detoxification is a highly specialized and targeted solution for the specific problem of acrolein in the bladder. Amifostine, with its systemic action and broader protective effects, is reserved for different clinical scenarios, such as preventing cisplatin-induced nephrotoxicity or radiation-induced xerostomia (dry mouth).[44] For the focused task of preventing oxazaphosphorine urotoxicity, Mesna's localized mechanism is generally preferred as it avoids the potential for systemic side effects associated with amifostine.

Mesna versus Hyperhydration

Forced diuresis through aggressive intravenous hyperhydration is a non-pharmacologic strategy to reduce hemorrhagic cystitis by diluting the concentration of toxic metabolites in the bladder and decreasing their contact time with the urothelium. While adequate hydration is a mandatory and complementary component of care for any patient receiving oxazaphosphorines [34], multiple studies have shown that Mesna provides a more reliable and superior level of protection, particularly with high-dose chemotherapy.

Animal studies have demonstrated that while both methods are effective, Mesna is significantly better than hyperhydration at preventing bladder edema and reducing the severity of histopathological lesions.[49] While some clinical trials in specific settings, such as bone marrow transplantation, have suggested equivalent efficacy between Mesna and hyperhydration [20], the broader consensus and standard practice is that the direct chemical neutralization offered by Mesna provides a more robust and dependable safeguard. Hyperhydration alone may not be sufficient to prevent toxicity from the high doses of ifosfamide and cyclophosphamide used in many modern protocols. Mesna provides a direct chemical antidote, adding a layer of security that dilution alone cannot match.

Regulatory and Manufacturing Landscape

The development of Mesna was a direct response to a critical unmet need in oncology. The powerful alkylating agent ifosfamide, developed by investigators at Asta-Werke in Germany, showed great promise but was severely limited by its profound urotoxicity.[51] This dose-limiting hemorrhagic cystitis spurred research into protective agents. Mesna was developed by the same group in the 1970s and early 1980s with the specific goal of achieving "regional detoxification" of the urinary tract.[10]

It was first introduced into widespread clinical practice in the 1980s.[53] In the United States, the injectable formulation of Mesna (as Mesnex®) received its initial FDA approval on December 30, 1988.[1] The oral tablet formulation was subsequently approved on March 21, 2002, providing a more convenient option for outpatient administration.[31]

The original developer and marketer of the brand name Mesnex® is Baxter Healthcare.[31] Following patent expirations, the market has become competitive, with several companies now manufacturing and marketing generic Mesna in both injectable and oral forms. Key players in the generic market include Fresenius Kabi USA, Gland Pharma, Hikma Pharmaceuticals, and Sagent Pharmaceuticals.[31]

Conclusion and Expert Insights

Coenzyme M, in its pharmaceutical form Mesna, stands as a cornerstone of supportive care in modern oncology. Its journey from discovery to standard of care is a compelling example of rational drug development, where a precise understanding of a specific, dose-limiting chemotherapy toxicity led to the creation of a highly effective and targeted antidote. The agent's value does not lie in treating cancer itself, but in its critical enabling role: by mitigating the risk of severe hemorrhagic cystitis, Mesna permits the safe and effective use of potent, often life-saving, doses of ifosfamide and cyclophosphamide.

The pharmacological elegance of Mesna resides in its mechanism of regional detoxification, a process driven entirely by its intrinsic pharmacokinetic properties. The rapid systemic oxidation to an inactive metabolite, followed by renal filtration and local reactivation in the urinary tract, represents a highly efficient and targeted drug delivery system that minimizes systemic risk while maximizing local protection. This unique profile has established its superiority over less effective (N-acetylcysteine), less targeted (amifostine), and less reliable (hyperhydration alone) uroprotective strategies.

For the practicing clinician, this monograph underscores two critical points. First is the absolute necessity of adhering to the precisely timed, weight-based dosing schedules. The efficacy of Mesna is inextricably linked to the synchronization of its presence in the bladder with the excretion of acrolein; failure to follow the prescribed schedule negates its protective benefit. Second is the need for vigilant monitoring for its most serious adverse effects: severe systemic hypersensitivity and dermatologic reactions. An awareness of the heightened risk in patients with pre-existing autoimmune disorders is essential for proactive risk management.

Looking forward, the story of Mesna may not be complete. While its role in uroprotection is secure, ongoing investigational studies into its antioxidant and mucolytic properties suggest the potential for new therapeutic applications, for example in mitigating anthracycline-induced toxicities or preventing post-procedural inflammation. Thus, a molecule first identified as a cofactor in ancient microbes and later synthesized to solve a specific chemotherapy problem may yet find new ways to improve patient outcomes across a broader medical landscape.

Works cited

1. Coenzyme M: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed July 28, 2025, https://go.drugbank.com/drugs/DB09110
2. Buy 2-Mercaptoethanesulfonic acid (EVT-298592) | 3375-50-6 - EvitaChem, accessed July 28, 2025, https://www.evitachem.com/product/evt-298592
3. Mesna - StatPearls - NCBI Bookshelf, accessed July 28, 2025, https://www.ncbi.nlm.nih.gov/books/NBK556021/
4. Mesna: MedlinePlus Drug Information, accessed July 28, 2025, https://medlineplus.gov/druginfo/meds/a613013.html
5. What is the mechanism of Mesna? - Patsnap Synapse, accessed July 28, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-mesna
6. Coenzyme M biosynthesis | Keywords - UniProt, accessed July 28, 2025, https://www.uniprot.org/keywords/KW-0174
7. FULL PRESCRIBING INFORMATION 1 ... - accessdata.fda.gov, accessed July 28, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/019884s013lbl.pdf
8. Label: MESNA injection, solution - DailyMed, accessed July 28, 2025, https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2a2a526f-636b-7920-4261-6c626f612a2a
9. 2-Mercaptoethanesulfonic acid solution | CAS 3375-50-6 - Products - Hopax Fine Chemicals, accessed July 28, 2025, https://www.hopaxfc.com/en/product/2-mercaptoethanesulfonic-acid-solution-en
10. 2-Mercaptoethanesulfonic acid | 3375-50-6 - ChemicalBook, accessed July 28, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB8186041.htm
11. en.wikipedia.org, accessed July 28, 2025, https://en.wikipedia.org/wiki/Coenzyme_M
12. Mesna - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Mesna
13. CAS No : 3375-50-6 | Product Name : 2-Mercaptoethane-1-sulfonic Acid | Pharmaffiliates, accessed July 28, 2025, https://www.pharmaffiliates.com/en/3375-50-6-2-mercaptoethane-1-sulfonic-acid-pa270031052.html
14. Coenzyme m - Sigma-Aldrich, accessed July 28, 2025, https://www.sigmaaldrich.com/US/en/search/coenzyme-m?focus=products&page=1&perpage=30&sort=relevance&term=coenzyme%20m&type=product_name
15. Comparision of uroprotective activity of reduced glutathione with Mesna in Ifosfamide induced hemorrhagic cystitis in rats - PMC - PubMed Central, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3912792/
16. Mesna - DRUG NAME:, accessed July 28, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Mesna_monograph_1Nov07.pdf
17. Pharmacokinetics of an intravenous-oral versus intravenous-mesna regimen in lung cancer patients receiving ifosfamide., accessed July 28, 2025, http://ascopubs.org/doi/pdf/10.1200/jco.1998.16.2.616
18. Mesna - NCI, accessed July 28, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/mesna
19. Review of Advances in Uroprotective Agents for Cyclophosphamide ..., accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/27566144/
20. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy. - ASCO Publications, accessed July 28, 2025, https://ascopubs.org/doi/10.1200/JCO.1987.5.5.799
21. Refractory B Acute Lymphoblastic Leukemia Terminated Phase 1 / 2 Trials for Coenzyme M (DB09110) - DrugBank, accessed July 28, 2025, https://go.drugbank.com/indications/DBCOND0107329/clinical_trials/DB09110?phase=1%2C2&status=terminated
22. Multiple Myeloma Completed Phase 2 / 3 Trials for Coenzyme M (DB09110) - DrugBank, accessed July 28, 2025, https://go.drugbank.com/indications/DBCOND0028259/clinical_trials/DB09110?phase=2%2C3&status=completed
23. Mesna: Drug information, accessed July 28, 2025, https://doctorabad.com/uptodate/d/topic.htm?path=mesna-drug-information
24. Central Nervous System Embryonal Tumors Not Yet Recruiting Phase 0 Trials for Coenzyme M (DB09110) - DrugBank, accessed July 28, 2025, https://go.drugbank.com/indications/DBCOND0084751/clinical_trials/DB09110?phase=0&status=not_yet_recruiting
25. Efficacy and safety of ifosfamide and mesna in metastatic castration-resistant prostate cancer after taxane-based chemotherapy and novel hormonal therapy failure. - ASCO Publications, accessed July 28, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.174
26. Clinical Trials Using Mesna - NCI, accessed July 28, 2025, https://www.cancer.gov/research/participate/clinical-trials/intervention/mesna
27. Mesna - brand name list from Drugs.com, accessed July 28, 2025, https://www.drugs.com/ingredient/mesna.html
28. Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release | ClinicalTrials.gov, accessed July 28, 2025, https://clinicaltrials.gov/study/NCT01205503
29. Efficacy of 2‐Mercaptoethane Sulfonate Sodium (MESNA) in the Prevention of Pancreatitis After Endoscopic Retrograde Cholangiopancreatography: A Randomized Open Label Trial - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11743974/
30. Mesna Injection, for intravenous use - Fresenius Kabi USA, accessed July 28, 2025, http://editor.fresenius-kabi.us/PIs/US-PH-Mesna-Inj-FK-45888E-10-2014-PI.pdf
31. Generic Mesnex Availability - Drugs.com, accessed July 28, 2025, https://www.drugs.com/availability/generic-mesnex.html
32. Mesna (intravenous route) - Side effects & uses - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/mesna-intravenous-route/description/drg-20064689
33. Generic MESNA INN equivalents, pharmaceutical patent expiry and freedom to operate - DrugPatentWatch, accessed July 28, 2025, https://www.drugpatentwatch.com/p/generic/mesna
34. Mesna Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed July 28, 2025, https://www.drugs.com/dosage/mesna.html
35. mesna - Cancer Care Ontario, accessed July 28, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43806
36. Mesnex - Drug Summary - PDR.Net, accessed July 28, 2025, https://www.pdr.net/drug-summary/Mesnex-mesna-1733
37. PRODUCT MONOGRAPH Pr MESNA for Injection 100 mg / mL Uroprotector Fresenius Kabi Canada Ltd. Date of Revision, accessed July 28, 2025, https://pdf.hres.ca/dpd_pm/00042770.PDF
38. Mesna (Mesnex): Uses, Side Effects, Interactions, Pictures ... - WebMD, accessed July 28, 2025, https://www.webmd.com/drugs/2/drug-63807/mesnex-oral/details
39. Mesna injection - Cleveland Clinic, accessed July 28, 2025, https://my.clevelandclinic.org/health/drugs/20286-mesna-injection
40. Mesna - Treatment and side effects | Macmillan Cancer Support, accessed July 28, 2025, https://www.macmillan.org.uk/cancer-information-and-support/treatments-and-drugs/mesna
41. Mesna (Mesnex®) | OncoLink, accessed July 28, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/mesna-mesnex-R
42. Comparison of N-acetylcysteine and mesna as uroprotectors with ..., accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/1428725/
43. Cyclophosphamide and Ifosfamide: Role of Uroprotective Agents, accessed July 28, 2025, https://www.tandfonline.com/doi/pdf/10.3109/07357909009017581
44. Chemoprotective Agents: Amifostine, Mesna, Dexrazoxane - Chemocare, accessed July 28, 2025, https://chemocare.com/what-is-chemotherapy/chemoprotective-agents
45. Comparison of uroprotective efficacy of mesna and amifostine in ..., accessed July 28, 2025, http://www.bioline.org.br/pdf?cn06002
46. The potential of amifostine: from cytoprotectant to therapeutic agent - Haematologica, accessed July 28, 2025, https://www.haematologica.org/article/view/1518/6730
47. Comparison of uroprotective efficacy of mesna and amifostine in Cyclophosphamide- induced hemorrhagic cystitis in rats. - IMSEAR, accessed July 28, 2025, https://imsear.searo.who.int/items/3ea53c14-5ebf-45c9-a863-b3379bf07ccc
48. Supportive drugs | Canadian Cancer Society, accessed July 28, 2025, https://cancer.ca/en/treatments/treatment-types/supportive-drugs
49. Experimental study of Comparison of Uro -protective efficacy of Mesna versus Hyperhydration in Cyclophosphamide-induced haemorrhagic Cystitis in Rats | ClinicSearch, accessed July 28, 2025, https://www.clinicsearchonline.org/article/experimental-study-of-comparison-of-uro--protective-efficacy-of-mesna-versus-hyperhydration-in-cyclophosphamide-induced-haemorrhagic-cystitis-in-rats
50. (PDF) Experimental study: a comparison of the uro-protective ..., accessed July 28, 2025, https://www.researchgate.net/publication/380509987_Experimental_study_a_comparison_of_the_uro-protective_efficacy_of_mesna_with_hyperhydration_in_cyclophosphamide-induced_haemorrhagic_cystitis_in_sprague_dawley_rats
51. The history of ifosfamide - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/1485170/
52. The development of mesna for regional detoxification - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/6414694/
53. What is Mesna used for? - Patsnap Synapse, accessed July 28, 2025, https://synapse.patsnap.com/article/what-is-mesna-used-for
54. Mesna Alternatives Compared - Drugs.com, accessed July 28, 2025, https://www.drugs.com/compare/mesna